Rockville, MD, United States of America

Natalia Gorlatova

This inventor holds 1 USPTO granted patent. Top assignees: American National Red Cross, Wyeth. Active years: 2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Natalia Gorlatova. Retrieved from https://idiyas.com/inventor/natalia-gorlatova

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Natalia Gorlatova: Pioneering Proteinase-Inhibitors

Introduction: Natalia Gorlatova, an accomplished inventor based in Rockville, MD, has made significant contributions to the field of biochemistry and drug design through her innovative research. With a focus on mutant proteinase-inhibitors, her work has opened new avenues for therapeutic development.

Latest Patents: Natalia holds a patent for "Mutant proteinase-inhibitors and uses thereof." This patent encompasses a library of mutants of metastable proteins, specifically proteinase inhibitors, which can be screened for their ability to bind antibodies. This method offers invaluable drug-design insights that were previously unavailable, ultimately leading to the development of mutant proteinase inhibitors with specific mutations that alter their interaction with anti-proteinase inhibitor antibodies.

Career Highlights: Throughout her career, Natalia has worked at several reputable organizations, including the American National Red Cross and Wyeth. Her experience in these institutions has allowed her to collaborate on various projects, enhancing her expertise in the field.

Collaborations: In her professional journey, Natalia has worked alongside notable colleagues, including Daniel A. Lawrence and David LeRoy Crandall. Their collaborations have contributed to the richness of her research and the successful application of her patented innovations.

Conclusion: Natalia Gorlatova's pioneering work in developing mutant proteinase-inhibitors represents a significant advancement in drug design. Her contributions not only benefit the scientific community but also pave the way for potential new therapies that can improve patient outcomes in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…